204 related articles for article (PubMed ID: 27884555)
1. After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
Grinfeld J; Godfrey AL
Blood Rev; 2017 May; 31(3):101-118. PubMed ID: 27884555
[TBL] [Abstract][Full Text] [Related]
2. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
Shi Y; Xu C
Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
[TBL] [Abstract][Full Text] [Related]
3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
4. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
5. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
James C
Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
[TBL] [Abstract][Full Text] [Related]
6. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
7. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
8. Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS; Casolari DA; Moore S; Nguyen T; Van Velzen MJM; Zantomio D; Scott HS; D'Andrea RJ; Hahn CN; Ross DM
Br J Haematol; 2017 Jul; 178(2):333-336. PubMed ID: 27136492
[No Abstract] [Full Text] [Related]
9. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
[TBL] [Abstract][Full Text] [Related]
10. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.
Swierczek S; Nausova J; Jelinek J; Liu E; Roda P; Kucerova J; Jarosova M; Urbankova H; Indrak K; Prchal JT; Divoky V
Am J Hematol; 2013 Feb; 88(2):157-8. PubMed ID: 23280542
[TBL] [Abstract][Full Text] [Related]
11. A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
Chapeau EA; Mandon E; Gill J; Romanet V; Ebel N; Powajbo V; Andraos-Rey R; Qian Z; Kininis M; Zumstein-Mecker S; Ito M; Hynes NE; Tiedt R; Hofmann F; Eshkind L; Bockamp E; Kinzel B; Mueller M; Murakami M; Baffert F; Radimerski T
PLoS One; 2019; 14(10):e0221635. PubMed ID: 31600213
[TBL] [Abstract][Full Text] [Related]
12. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
Roda P; Ferrari A; Tang X; Erlich P; Eisenhower C; Patel MD; Irvin-Barnwell EA
Ann Hematol; 2014 Sep; 93(9):1467-72. PubMed ID: 24687383
[TBL] [Abstract][Full Text] [Related]
13. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
14. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
15. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
16. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
[TBL] [Abstract][Full Text] [Related]
17. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
18. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
[TBL] [Abstract][Full Text] [Related]
19. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
20. Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.
Gou P; Zhang W; Giraudier S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]